The Effect of Oral Administration of PUFAs on the Matrix Metalloproteinase Expression in Gastric Adenocarcinoma Patients Undergoing Chemotherapy

Khojastehfard, Mehran; Dolatkhah, Homayun; Somi, Mohammad‐Hossein; Ahmad, Saeed Nazari Soltan; Estakhri, Rasoul; Sharifi, Rasoul; Naghizadeh, Mohsen; Rahmati-Yamchi, Mohammad

doi:10.1080/01635581.2018.1506494

Cited by 8 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a decreased expression of both MMP-1 and MMP-2 in gastric cancer tumors in patients treated with cisplatin and supplemented with PUFAs was also observed [153]. On the other hand, in the study aimed to highlight the effects of LA stimulation in OCUM-2MD3 gastric carcinoma cells in vitro, Matsuoka et al (2010) found that metabolites of this n-6 FA caused an increase in phosphorylation of extracellular signal-regulated kinase (ERK) as an effect of increased COX-1 activity, which resulted in increased invasiveness of the cells [154].…”

Section: Antiangiogenic and Antimetastatic Effectsmentioning

confidence: 89%

Effects of Dietary n–3 and n–6 Polyunsaturated Fatty Acids in Inflammation and Cancerogenesis

Liput

Lepczyński

Ogłuszka

et al. 2021

IJMS

141

View full text Add to dashboard Cite

The dietary recommendation encourages reducing saturated fatty acids (SFA) in diet and replacing them with polyunsaturated fatty acids (PUFAs) n–3 (omega–3) and n–6 (omega–6) to decrease the risk of metabolic disturbances. Consequently, excessive n–6 PUFAs content and high n–6/n–3 ratio are found in Western-type diet. The importance of a dietary n–6/n–3 ratio to prevent chronic diseases is linked with anti-inflammatory functions of linolenic acid (ALA, 18:3n–3) and longer-chain n–3 PUFAs. Thus, this review provides an overview of the role of oxylipins derived from n–3 PUFAs and oxylipins formed from n–6 PUFAs on inflammation. Evidence of PUFAs’ role in carcinogenesis was also discussed. In vitro studies, animal cancer models and epidemiological studies demonstrate that these two PUFA groups have different effects on the cell growth, proliferation and progression of neoplastic lesions.

show abstract

Section: Antiangiogenic and Antimetastatic Effectsmentioning

confidence: 89%

Effects of Dietary n–3 and n–6 Polyunsaturated Fatty Acids in Inflammation and Cancerogenesis

Liput

Lepczyński

Ogłuszka

et al. 2021

IJMS

141

View full text Add to dashboard Cite

show abstract

“…(6) Other machanisms. Some studies have found that PUFAs inhibit the expression of MMPs in gastric cancer and interferes with tumor cell invasion and metastasis [127]. Simultaneously, ω-6 PUFAs was pointed out through PPARγ regulated downstream target genes to reduce synthesis of inflammatory mediators [128,129].…”

Section: The Role Of Polyunsaturated Fatty Acids In Tumormentioning

confidence: 99%

Targeting the Key Enzymes of Abnormal Fatty Acid β-oxidation as a Potential Strategy for Tumor Therapy

Chen¹,

Yang²,

Sun³

et al. 2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Fatty acid metabolism has attracted extensive attention for its key role in the occurrence and development of tumors. Fatty acids not only participate in the biosynthesis of phospholipids in the membrane to overcome the demand for rapidly proliferating membrane lipids but also provide ATP, signaling molecules, and NADPH through β-oxidation to maintain tumor survival and growth. However, the specific role of fatty acid β-oxidation in tumors and the description of multiple potential targets in this process are not comprehensive and systematic. Therefore, this review summarizes the function of fatty acid β-oxidation in tumors and studies of key enzymes that catalyze related reactions in various stages to improve the overall understanding of fatty acid β-oxidation and search for novel tumor treatment strategies and ideas.

show abstract

“…A spectrum of cancers including breast [7][8][9][10][11][12][13][14][15][16], head and neck [15,[17][18][19], gastrointestinal [14,[20][21][22][23][24][25][26][27], gastric [21,[28][29][30][31], colorectal/rectal [21,[32][33][34][35][36][37][38][39][40][41][42][43][44][45], esophageal [15,19,21,46,47], leukemia/lymphoma [48], lung [14,15,...…”

Section: Overview Of Studiesmentioning

confidence: 99%

“…Of the total supplementation, DHA concentrations ranged from 0 to 2 g, with 86% of the studies providing 1 g or less per day. When capsules were provided concomitant with chemotherapy the intervention length was 6-24 weeks and equivalent to the duration of chemotherapy [7][8][9][10][11]16,20,26,27,[30][31][32][33][34]45,[48][49][50][51]56,63]. In the absence of chemotherapy, supplementation was provided for 1-6 months [12][13][14]35,36,52,57].…”

Section: N-3 Type Amount Prescribed and Intervention Lengthmentioning

confidence: 99%

“…Darwito et al found decreased Ki67 expression in breast cancer patients receiving 1 g per day of n-3 supplement (39.2 ± 5.3 versus 42.4 ± 4.8, p = 0.03) [8], while there were no observed changes in the Ki67 proliferation index in patients with colorectal cancer and liver metastases when supplemented with 2 g of EPA per day [36]. Other experimentally relevant markers have been assessed in supplementation studies that suggest efficacy of n-3 fatty acids in modulating cancer outcomes including decreased vascular endothelial growth factor (VEGF) [47] and oxidative status [50], increased glutathione reductase, antioxidant status [16], superoxide dismutase [16,20] and phagocytosis and H 2 O 2 [20] in plasma or peripheral blood mononuclear cells and decreased VEGF [8], carcinoembryonic antigen [34] and gene expression of matrix metalloproteinase (MMP)-1 and MMP-9 [30] in tumors.…”

Section: Additional Parametersmentioning

confidence: 99%

See 1 more Smart Citation

N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence

Newell

Mazurak

Postovit

2021

Cancers

View full text Add to dashboard Cite

This scoping review examines the evidence for n-3 long-chain polyunsaturated fatty acid [LCPUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] supplementation in clinical cancer therapy. A comprehensive literature search was performed to identify relevant clinical intervention studies conducted through August 2020. Fifty-seven unique cancer trials, assessing EPA and/or DHA supplementation pre- or post-treatment, concomitant with neoadjuvant chemotherapy, radiation or surgery, or in palliative therapy were included. Breast, head and neck, gastrointestinal, gastric, colorectal/rectal, esophageal, leukemia/lymphoma, lung, multiple myeloma and pancreatic cancers were investigated. Across the spectrum of cancers, the evidence suggests that supplementation increased or maintained body weight, increased progression-free and overall survival, improved overall quality of life, resulted in beneficial change in immune parameters and decreased serious adverse events. Taken together, the data support that EPA and/or DHA could be used to improve outcomes important to the patient and disease process. However, before incorporation into treatment can occur, there is a need for randomized clinical trials to determine the dose and type of n-3 LCPUFA intervention required, and expansion of outcomes assessed and improved reporting of outcomes.

show abstract

The Effect of Oral Administration of PUFAs on the Matrix Metalloproteinase Expression in Gastric Adenocarcinoma Patients Undergoing Chemotherapy

Cited by 8 publications

References 40 publications

Effects of Dietary n–3 and n–6 Polyunsaturated Fatty Acids in Inflammation and Cancerogenesis

Effects of Dietary n–3 and n–6 Polyunsaturated Fatty Acids in Inflammation and Cancerogenesis

Targeting the Key Enzymes of Abnormal Fatty Acid β-oxidation as a Potential Strategy for Tumor Therapy

N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence

Contact Info

Product

Resources

About